FANGZHOU JIANKE (06086) has announced that it expects the Group's revenue for the 2025 fiscal year to be approximately RMB 3.50 billion to RMB 3.55 billion. This represents an increase of about 30.0% compared to the revenue of RMB 2.7074 billion recorded in 2024. The Group also anticipates achieving a net profit ranging from approximately RMB 7 million to RMB 10 million for the reporting period. This marks a significant turnaround from the pre-tax net loss of RMB 855 million incurred in the 2024 fiscal year. According to the announcement, the expected revenue growth is primarily attributable to the sustained expansion of the company's business segment focused on consumers. This growth is driven by the company's success in attracting more patients and doctors to its platform. The shift from loss to profit is mainly due to the increase in revenue, coupled with a reduction in equity-settled, share-based payment transactions.